S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:HOOK - Hookipa Pharma Stock Price, Forecast & News

$11.81
-0.18 (-1.50 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$11.50
Now: $11.81
$11.99
50-Day Range
$11.13
MA: $12.07
$13.80
52-Week Range
$6.06
Now: $11.81
$14.76
Volume67,942 shs
Average Volume81,921 shs
Market Capitalization$254.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOOK
CUSIPN/A
CIKN/A
Phone431-890-6360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees56
Market Cap$254.97 million
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.


Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.45) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.66) by $0.21. The company earned $2.04 million during the quarter, compared to the consensus estimate of $2.35 million. View Hookipa Pharma's Earnings History.

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Hookipa Pharma.

What price target have analysts set for HOOK?

5 Wall Street analysts have issued 12-month target prices for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they expect Hookipa Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.

What is the consensus analysts' recommendation for Hookipa Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.

Has Hookipa Pharma been receiving favorable news coverage?

Media headlines about HOOK stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Hookipa Pharma earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Hookipa Pharma.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a decline in short interest in January. As of January 31st, there was short interest totalling 196,700 shares, a decline of 33.9% from the January 15th total of 297,700 shares. Based on an average daily trading volume, of 105,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.7% of the shares of the stock are short sold. View Hookipa Pharma's Current Options Chain.

Who are some of Hookipa Pharma's key competitors?

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Pfizer (PFE), Exxon Mobil (XOM), Alector (ALEC), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Verizon Communications (VZ), Akero Therapeutics (AKRO) and Axsome Therapeutics (AXSM).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the folowing people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (2.27%), Geode Capital Management LLC (0.48%), State Street Corp (0.43%), Bank of New York Mellon Corp (0.13%), Charles Schwab Investment Management Inc. (0.10%) and UBS Group AG (0.06%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr. View Institutional Ownership Trends for Hookipa Pharma.

Which institutional investors are selling Hookipa Pharma stock?

HOOK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Bank of America Corp DE. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky and Klaus Orlinger. View Insider Buying and Selling for Hookipa Pharma.

Which institutional investors are buying Hookipa Pharma stock?

HOOK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, UBS Group AG, Barclays PLC and American International Group Inc.. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker and Sofinnova Capital Vi Fcpr. View Insider Buying and Selling for Hookipa Pharma.

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $11.81.

How big of a company is Hookipa Pharma?

Hookipa Pharma has a market capitalization of $254.97 million. Hookipa Pharma employs 56 workers across the globe.View Additional Information About Hookipa Pharma.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is http://www.hookipapharma.com/.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 Fifth Avenue 72nd Floor Suite 7240, New York NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]


MarketBeat Community Rating for Hookipa Pharma (NASDAQ HOOK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote "Outperform" if you believe HOOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel